{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:49:45Z","timestamp":1793742585239,"version":"4.6.1"},"reference-count":124,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/14737140.2026.2685304","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:18:12Z","timestamp":1780499892000},"page":"1317-1335","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Antibody\u2013drug conjugates: a practical review on clinical management of toxicities"],"prefix":"10.1080","volume":"26","author":[{"given":"Antonio","family":"De Palma","sequence":"first","affiliation":[{"name":"Sapienza University, Policlinico Umberto I","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marenco","sequence":"additional","affiliation":[{"name":"Sapienza - University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Mancini","sequence":"additional","affiliation":[{"name":"Sapienza University, Policlinico Umberto I","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocenza","family":"Palaia","sequence":"additional","affiliation":[{"name":"Sapienza University, Policlinico Umberto I","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Barchiesi","sequence":"additional","affiliation":[{"name":"Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violante","family":"Di Donato","sequence":"additional","affiliation":[{"name":"Sapienza University, Policlinico Umberto I","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Perniola","sequence":"additional","affiliation":[{"name":"Sapienza University, Policlinico Umberto I","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Petrella","sequence":"additional","affiliation":[{"name":"Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Muzii","sequence":"additional","affiliation":[{"name":"Sapienza University, Policlinico Umberto I","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tomao","sequence":"additional","affiliation":[{"name":"Sapienza University, Policlinico Umberto I","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102943"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3084"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00783-w"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500262"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8CS00676H"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.042"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01519-0"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18020180"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.008"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104979"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01500"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020396"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040561"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136969"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18081198"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102113"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01720-3"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.1c00029"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.3c00363"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01281-4"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30097-X"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.001"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00064-0"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00140-2"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3162"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4557"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0201-0"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0541"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.08.011"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1036026"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.775113"},{"key":"e_1_3_5_44_1","unstructured":"European Medicines Agency. Kadcyla (trastuzumab emtansine) EPAR \u2013 product information. European Medicines Agency website; 2023 [cited 2026 Feb]."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0012"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3980"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406070"},{"key":"e_1_3_5_48_1","unstructured":"Genentech Inc. KADCYLA (ado-trastuzumab emtansine) for injection for intravenous use: prescribing information. U.S. Food and Drug Administration; 2025 [cited 2026 Feb]."},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49251-5"},{"key":"e_1_3_5_50_1","unstructured":"Gilead Sciences Inc. TRODELVY\u00ae (sacituzumab govitecan-hziy) for injection for intravenous use: prescribing information. U.S. Food and Drug Administration. 2020 [cited 2026 Feb."},{"key":"e_1_3_5_51_1","volume-title":"Trodelvy (sacituzumab govitecan) EPAR \u2013 medicine overview","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. Trodelvy (sacituzumab govitecan) EPAR \u2013 medicine overview. Amsterdam, Netherlands: European Medicines Agency website; 2021 [cited 2025 Aug 21]. Accessed February 2026."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70096"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2962"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2404457"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221118370"},{"key":"e_1_3_5_57_1","volume-title":"Tivdak (tisotumab vedotin) EPAR \u2013 medicine overview","author":"European Medicines Agency","year":"2025","unstructured":"European Medicines Agency. Tivdak (tisotumab vedotin) EPAR \u2013 medicine overview. Amsterdam, Netherlands: European Medicines Agency website. 2025 [cited 2026 Feb]."},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313811"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110816"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"e_1_3_5_62_1","volume-title":"Padcev (enfortumab vedotin) EPAR \u2013 Medicine overview","author":"European Medicines Agency","year":"2022","unstructured":"European Medicines Agency. Padcev (enfortumab vedotin) EPAR \u2013 Medicine overview. Amsterdam, Netherlands: European Medicines Agency website; 2022 [cited 2025 Sep]. Accessed February 2026."},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.016"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00158-5"},{"key":"e_1_3_5_68_1","volume-title":"Datroway (datopotamab deruxtecan) EPAR \u2013 product information","author":"European Medicines Agency","year":"2025","unstructured":"European Medicines Agency. Datroway (datopotamab deruxtecan) EPAR \u2013 product information. Amsterdam, Netherlands: European Medicines Agency website. 2025 [cited 2026 Feb]. Accessed February 2026."},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02185-x"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104589"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1388"},{"key":"e_1_3_5_72_1","volume-title":"Elahere (mirvetuximab soravtansine) EPAR \u2013 medicine overview","author":"European Medicines Agency","year":"2024","unstructured":"European Medicines Agency. Elahere (mirvetuximab soravtansine) EPAR \u2013 medicine overview. Amsterdam, Netherlands: European Medicines Agency website; 2024 [cited 2026 Jan]. Accessed February 2026."},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35349"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14686"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01736-w"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00047"},{"key":"e_1_3_5_79_1","volume-title":"Enhertu (trastuzumab deruxtecan) EPAR \u2013 medicine overview","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. Enhertu (trastuzumab deruxtecan) EPAR \u2013 medicine overview. Amsterdam, Netherlands: European Medicines Agency website. 2021 [cited 2026 Feb]."},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.010"},{"key":"e_1_3_5_81_1","unstructured":"U.S. Food and Drug Administration. FDA approves mirvetuximab soravtansine-gynx for FR\u03b1-positive platinum-resistant epithelial ovarian fallopian tube or primary peritoneal cancer. U.S. Food and Drug Administration website; 2024 [cited 2026 Feb]."},{"key":"e_1_3_5_82_1","volume-title":"FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. Silver Spring, Maryland, USA: U.S. Food and Drug Administration website; 2024 [cited 2026 Feb]."},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf311"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09918-4"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103309"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70060"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1414.035"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15507"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.541155"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1463"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.016"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23370"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.10.002"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30312-1"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6160"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf298"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01075-8"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00958-6"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108425"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3595"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110935"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110408"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111144"},{"key":"e_1_3_5_108_1","volume-title":"American academy of ophthalmology","author":"Meghan SSMAVFMNPM","year":"2025","unstructured":"Meghan SSMAVFMNPM, Berkenstock MD. Antibody-drug conjugates and ocular toxicities: a call for standardized guidelines. In: American academy of ophthalmology. San Francisco, California, USA; 2025."},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102867"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000001063"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26114996"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2251380"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1425617"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33474"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08043-4"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1873950"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143675"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17850"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.2567"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007324"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202500305"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2708240"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00869-w"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3656"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17091164"}],"updated-by":[{"DOI":"10.1080\/14737140.2026.2687996","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000}}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2685304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737140.2026.2685304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2685304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:45:01Z","timestamp":1790865901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2026.2685304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":124,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/14737140.2026.2685304"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2026.2685304","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}